Grace Therapeutics, Inc. (GRCE) stock
GRCENasdaqPharmaceutical PreparationsFiscal year ends March 31
$1.75−0.06 (-3.31%)
Close on Nov 16, 2026Market cap $36.81MP/E –Yield –
Grace Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Grace Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$10.29M. For fiscal 2026 it was -$8.87M. The highest annual figure on record is -$8.87M in fiscal 2026.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | -$8.87M | – |
| FY2025 | Mar 31, 2025 | -$14.90M | – |
| FY2024 | Mar 31, 2024 | -$12.33M | – |
| FY2023 | Mar 31, 2023 | -$15.91M | – |
| FY2022 | Mar 31, 2022 | -$17.23M | – |
| FY2021 | Mar 31, 2021 | -$14.32M | – |
| FY2020 | Mar 31, 2020 | -$22.95M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | -$3.22M | – |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$1.70M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$2.23M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$3.14M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$1.80M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$2.95M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$4.12M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$4.24M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$3.60M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$2.09M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$1.89M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$2.11M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$6.24M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$3.33M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$3.72M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$3.44M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$5.43M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$3.15M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$4.58M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$6.10M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$3.40M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$1.76M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$4.21M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$4.18M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$4.17M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$22.94M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$7.10M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$6.15M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$6.82M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$24.79M | – |
See a number that looks wrong?